Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Aug 21, 2013; 19(31): 5187-5194
Published online Aug 21, 2013. doi: 10.3748/wjg.v19.i31.5187
Published online Aug 21, 2013. doi: 10.3748/wjg.v19.i31.5187
Cases | Authors | Age (yr)/sex | Type | Site of metastasis | Chemotherapy regimen | Response | Prognosis (mo) |
1 | Present case | 65/F | Recurrent | Liver | EMA/CO | CR | 115 NED |
2 | Waseda et al[5] | 68/M | Unresectable | Liver | EP | CR | 24 NED |
3 | Shastri et al[8] | 44/M | Unresectable | Liver | BEP | Size reduction | 12 DOD |
4 | Shimuzu et al[9] | 43/F | Unresectable | Distant lymph nodes | TS-1/CDDP | Size reduction | 7 DOD |
5 | Yoon et al[10] | 62/M | Unresectable | Liver | 5-FU/USAN/L-OHP | Progression | 16 DOD |
PTX/CDDP | Progression | ||||||
5-FU/USAN/CPT-11 | Progression | ||||||
BEP | Progression | ||||||
EMA/CO | Progression | ||||||
VIP | Progression | ||||||
6 | Yoon et al[10] | 45/M | Unresectable | Liver | BEP | Progression | 12 DOD |
VIP | Progression | ||||||
EMA/CO | Progression | ||||||
5-FU/USAN/CPT-11 | Progression | ||||||
7 | Kanemura et al[11] | 79/M | Recurrent | No data | TS-1/PTX | Progression | 5 DOD |
8 | Yasumoto et al[12] | 76/F | Unresectable | Liver | 5-FU | Progression | 1 DOD |
9 | Mori et al[13] | 36/F | Recurrent | Brain and lung | EMA/CO | CR | 54 NED |
10 | Enokido et al[14] | 54/M | Unresectable | Liver | TS-1 | Progression | 3 DOD |
11 | Adachi et al[15] | 78/M | Unresectable | Liver | TS-1 | CR | 12 NED |
12 | Kishimoto et al[16] | 69/M | Recurrent | Liver | Epi-ADM/MMC (TACE) | Progression | 17 DOD |
5-FU (HAI) | Progression | ||||||
UFT | Progression | ||||||
13 | Kawaguchi et al[17] | 60 M | Recurrent | Liver | MTX/BLM/CDDP/CPA | Progression | 5 DOD |
14 | Liu et al[18] | 36/F | Unresectable | Colon (infiltration) | BEP | Size reduction | 6 DOD |
VBL/IFM/CDDP | Progression | ||||||
15 | Inaki et al[19] | 56/M | Recurrent | Liver | MAC (second-line after UFT as adjuvant) | Progression | 3 DOD |
16 | Bayhan et al[20] | 26/F | Recurrent | Lung | MAC | Size reduction | 18 NED |
17 | Satoh et al[21] | 58/M | Recurrent | Paraaortic lymph nodes | VP-16/CDDP | Progression | 6 DOD |
18 | Kinoshita et al[22] | 74/M | Unresectable | Liver | MTX | Progression | 3 AWD |
19 | Imai et al[23] | 63/F | Recurrent | Liver | MA | Progression | 3 DOD |
20 | Fujimoto et al[24] | 57/M | Recurrent | Liver | MAC | Progression | 6 DOD |
21 | Ogura et al[25] | 45/F | Recurrent | Liver | 5-FU/MMC/Epi-ADM (HAI) | Size reduction | 10 DOD |
VP-16/CDDP | Progression | ||||||
22 | Kan et al[26] | 67/M | Unresectable | Liver | 5'DFUR/CDDP | Size reduction | 10 DOD |
5'DFUR/CDDP/VP-16 | Progression | ||||||
MTX | Progression | ||||||
23 | Saito et al[27] | 57/M | Recurrent | CEA elevation | 5-FU/CDDP (second-line after Tegafur as adjuvant) | SD | 12 AWD |
24 | Imatake et al[28] | 50/M | Unresectable | Liver | MMC/5-FU/lentinan | Progression | 2 DOD |
25 | Okada et al[29] | 57/F | Recurrent | hCG elevation | VAC | Progression | 7 DOD |
26 | Kobayashi et al[30] | 60/M | Unresectable | Liver | MTX/ADM (HAI) | Progression | 5 DOD |
27 | Masuda et al[31] | 79/M | Unresectable | Liver | UFT | Progression | 1.5 DOD |
- Citation: Takahashi K, Tsukamoto S, Saito K, Ohkohchi N, Hirayama K. Complete response to multidisciplinary therapy in a patient with primary gastric choriocarcinoma. World J Gastroenterol 2013; 19(31): 5187-5194
- URL: https://www.wjgnet.com/1007-9327/full/v19/i31/5187.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i31.5187